Sun Pharmaceutical Industries Limited (SUNPHARMA) — Board Meeting | 31 July 2026(3 announcements)

Sun Pharmaceutical Industries Limited approved unaudited Q1 FY27 standalone and consolidated financial results for the quarter ended June 30, 2026, during its board meeting on July 31, 2026. The results, prepared under SEBI Listing Regulations and Ind AS 34, include impacts from the New Labour Codes, deferred tax remeasurement under the concessional tax regime, and exceptional items related to subsidiary mergers and acquisition costs. The limited review by SR B C & CO LLP confirmed no material misstatements across 72 entities. Key financial highlights include 10.1% YoY sales growth to Rs 151,836 million, EBITDA margin of 28.9%, and adjusted net profit of Rs 30,894 million. The company also disclosed a definitive agreement to acquire Organon & Co. for $11.75 billion, with tax credits from labour code implementation and deferred tax adjustments totaling Rs 1,030 million.

Sun Pharmaceutical Industries Limited announced that all resolutions proposed at its 34th Annual General Meeting held on 31 July 2026 were passed by shareholders with the requisite majority, as confirmed by the Scrutinizer’s report submitted to the company.

Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on 31 July 2026 via video conference, where shareholders approved all proposed resolutions including adoption of audited standalone and consolidated financial statements for FY26, final dividend of Rs. 5 per share, appointment of Whole-time Director Aalok Shanghvi, and ratification of auditor remuneration. Independent Director Andreas Busch was appointed for a five-year term. Chairman Dilip Shanghvi highlighted 11.9% consolidated revenue growth to Rs. 582 billion, 16.1% EBITDA growth, and 22% contribution of Innovative Medicines to sales, while announcing the proposed acquisition of Organon & Co. to expand into women's health and biosimilars.